| DB ID | MyCo_2312 |
| Title | The values of (1,3)-β-D-glucan and galactomannan in cases of invasive fungal rhinosinusitis |
| Year | 2020 |
| PMID | 33412381 |
| Fungal Diseases involved | Invasive fungal rhinosinusitis |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | The present retrospective study analysed the clinical data of 98 patients who were preliminarily diagnosed with “space-occupying lesions in the nasal cavity and sinuses” at Beijing Tongren Hospital affiliated to Capital Medical University between March 2011 and February 2017. The initial diagnosis did not exclude the possibility of IFRS in any of the 98 patients. These patients included 47 males and 51 females. The age of the patients ranged from 22 to 83 years (mean age: 56.7 ±13.4 years). |
| Cohort No. | 98 |
| Age Group | 22-83 |
| P Value | None |
| Sensitivity | 0.6 |
| Specificity | 0.923 |
| Positive Predictive Value | 0.5 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal rhinosinusitis (IFRS) is a severe disease caused by the invasion of fungal hyphae into certain structures, including the mucosa, submucosa, blood vessels, and bones of the nasal cavity and paranasal sinuses. IFRS is clinically rare. IFRS lacks characteristic clinical manifestations at the early stages of the disease, which results in a delayed diagnosis. Upon seeking treatment, patients’ lesions have often invaded neighbouring structures and become difficult to distinguish from malignant tumours. Although advances have been made in the drug therapies and surgical interventions for IFRS, this disease currently has a mortality rate of 10–40% when not treated in a timely fashion. Therefore, the early diagnosis and treatment of IFRS are particularly important in clinical practice. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Fungus (1,3)-β-D-glucan Assay Kit [spectrophotometric method], Zhanjiang A & C Biological Ltd.), Platelia™ Aspergillus Antigen Kit [ELISA], Bio-Rad Laboratories, Inc.) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
